Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01661283
Other study ID # SARC016
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2012
Est. completion date December 2017

Study information

Verified date February 2019
Source Sarcoma Alliance for Research through Collaboration
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the clinical response rate of everolimus in combination with bevacizumab for patients with chemotherapy refractory sporadic or neurofibromatosis type 1 (NF1) associated malignant peripheral nerve sheath tumor (MPNST). To evaluate the toxicity and safety of everolimus in combination with bevacizumab in individuals with MPNST


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date December 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients 18 or older

- Unresectable or metastatic sporadic or NF1 associated high-grade MPNST

- Experienced progression after one or more prior regimens of cytotoxic chemotherapy

- Patients must be able to swallow tablets

- Patients must have measurable disease, defined as at least one tumor that is measurable

- Patients who develop a recurrence or progression (WHO criteria) of an MPNST in a previously radiated field may be enrolled if it has been at least 4 weeks since the last dose of radiation therapy

- Patients must have recovered from the toxic effects of all prior therapy before entering this study

- Adequate organ function

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Patents who received an anthracycline prior to enrollment must have an ejection fraction = 50%

- Subjects of childbearing potential requires acceptable form of birth control

- Informed consent

Exclusion Criteria:

- Patients currently receiving anticancer therapies or who have received anticancer therapies within 3 weeks of the start of study drug or patients receiving prior treatment with investigational drugs 4 weeks of the start of study drug

- Patients may not be currently receiving strong inhibitors of CYP3A4, and may not have received these medications within 1 week of entry

- Prior radiotherapy within 4 weeks of the start of study drug

- Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug,

- Patients who have not recovered from the side effects of any major surgery

- Patients that may require major surgery during the course of the study

- Less than 7 days have passed from core biopsies or other minor surgical procedures excluding placement of a vascular access device

- Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent(Topical or inhaled corticosteroids are allowed)

- Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases

- Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin

- Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study

- Female patients who are pregnant or breast feeding

- Patients who have received prior treatment with an mTOR inhibitor or bevacizumab

- Patients with known hypersensitivity to rapamycins

- concurrent use of anti-coagulant drugs

- Patients using Seville orange, star fruit, grapefruit and their juices, and St. John's Wort

- Patients taking enzyme inducing anticonvulsants

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
everolimus
10 mg tablet once daily
bevacizumab
10 mg/kg dose every 14 days

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States Johns Hopkins Baltimore Maryland
United States National Cancer Institute Bethesda Maryland
United States University of Alabama at Birmingham Birmingham Alabama
United States Massachusetts General Hospital Boston Massachusetts
United States Ann and Robert Lurie Children's Hospital of Chicago Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States University of Iowa Iowa City Iowa
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Pennsylvania Oncology Hematology Associates Philadelphia Pennsylvania
United States Washington University in St. Louis Saint Louis Missouri
United States Children's National Medical Center Washington District of Columbia

Sponsors (4)

Lead Sponsor Collaborator
Sarcoma Alliance for Research through Collaboration Genentech, Inc., Novartis Pharmaceuticals, United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease at = 4 Months Using World Health Organization (WHO) Criteria) of Everolimus in Combination With Bevacizumab Evaluate if the combination of the mTOR inhibitor everolimus combined with the angiogenesis inhibitor bevacizumab would result in a modest clinical benefit rate, which included confirmed partial and complete responses and disease stability for four or more treatment cycles based on WHO Response Criteria. Per WHO for target lesions: Complete Response (CR): Disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart.
Partial Response (PR): A > 50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive. Stable Disease (SD): A 50% decrease in total tumor area cannot be established nor has a 25% increase in the size of one or more measurable lesions been demonstrated.
Assessed at Baseline and prior to Cycle 3, 5, 7, 9, etc., for up to 2 years. 1 cycle =28 days
Secondary Spectrum of Germline NF1 Mutations in Individuals With NF1 Associated MPNSTs To evaluate the spectrum of germline NF1 mutations in individuals with NF1 associated MPNSTs greater than or equal to 4 months
Secondary Number of Participants With Response Stratified by Individuals With Sporadic or NF1 Associated MPNST To explore differences in the response rate to everolimus in combination with bevacizumab in individuals with sporadic and NF1 associated MPNST. Responses include confirmed partial and complete responses and disease stability for four or more treatment cycles based on WHO Response Criteria. Per WHO for target lesions: Complete Response (CR): Disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial Response (PR): A > 50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive. Stable Disease (SD): A 50% decrease in total tumor area cannot be established nor has a 25% increase in the size of one or more measurable lesions been demonstrated. Assessed at Baseline and prior to Cycle 3, 5, 7, 9, etc., for up to 2 years. 1 cycle =28 days
Secondary Relationship Between Response to Everolimus in Combination With Bevacizumab and the Presence of NF1 Mutations or NF1 Inactivation in MPNST Tumor Samples To explore the relationship between response to everolimus in combination with bevacizumab and the presence of NF1 mutations or NF1 inactivation in MPNST tumor samples greater than or equal to 4 months
Secondary Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Levels at Baseline and Pre-Cycles 3 and 5 To assess changes in Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Levels in peripheral blood specimens during treatment. Baseline, Pre-Cycle 3, Pre-Cycle 5
Secondary Utility of 3-D MRI Analysis in Comparison to 1-D and 2-D Measurements to More Sensitively Monitor Response to Everolimus in Combination With Bevacizumab To evaluate the utility of 3-D MRI analysis in comparison to 1-D and 2-D measurements to more sensitively monitor response to everolimus in combination with bevacizumab greater than or equal to 4 months
See also
  Status Clinical Trial Phase
Recruiting NCT04457258 - 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma Early Phase 1
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT04535713 - GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma Phase 2
Completed NCT03521531 - Burden and Medical Care of Sarcoma in Germany
Completed NCT02496520 - Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults Phase 1/Phase 2
Terminated NCT02054104 - Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Phase 1/Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT04052334 - Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma Phase 1
Completed NCT01593748 - A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Completed NCT01879085 - Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Phase 1/Phase 2
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Completed NCT01209598 - PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Phase 2
Completed NCT04553471 - Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers N/A
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2

External Links